Para-aminosalicylic acid as a lipid-lowering agent. 1978

B Vessby, and H Lithell, and J Boberg, and K Hellsing

The capacity of para-aminosalicylic acid (PAS) to lower initially high serum lipoprotein lipid concentrations was tested in a double-blind crossover study. Thirty patients who were on a lipid-lowering diet were treated with PAS (6 gm daily) for 4 wk. There was an average reduction of the serum triglyceride concentration of 28% (p less than 0.001) and of 12% of the serum cholesterol concentration (p less than 0.001) corresponding to a reduction of very low density lipoprotein (VLDL) triglycerides of 40% (p less than 0.001) and low density lipoprotein (LDL) cholesterol of 6% (p less than 0.05). In hypercholesterolemic patients, the LDL cholesterol reduction was 14% (p less than 0.001). In patients with hypertriglyceridemia type IV, the mean reduction of the VLDL triglyceride concentration was 47% (p less than 0.01), corresponding to a serum triglyceride reduction by 37% (p less than 0.01). In spite of the decrease of VLDL concentration, there was an unexpected reduction of the lipoprotein lipase activity in adipose tissue of 16% (p less than 0.02). The glucose tolerance and the serum insulin concentrations at fasting and after glucose injection were not changed.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008071 Lipoprotein Lipase An enzyme of the hydrolase class that catalyzes the reaction of triacylglycerol and water to yield diacylglycerol and a fatty acid anion. The enzyme hydrolyzes triacylglycerols in chylomicrons, very-low-density lipoproteins, low-density lipoproteins, and diacylglycerols. It occurs on capillary endothelial surfaces, especially in mammary, muscle, and adipose tissue. Genetic deficiency of the enzyme causes familial hyperlipoproteinemia Type I. (Dorland, 27th ed) EC 3.1.1.34. Heparin-Clearing Factor,Lipemia-Clearing Factor,Diacylglycerol Lipase,Diglyceride Lipase,Post-Heparin Lipase,Postheparin Lipase,Postheparin Lipoprotein Lipase,Factor, Heparin-Clearing,Factor, Lipemia-Clearing,Heparin Clearing Factor,Lipase, Diacylglycerol,Lipase, Diglyceride,Lipase, Lipoprotein,Lipase, Post-Heparin,Lipase, Postheparin,Lipase, Postheparin Lipoprotein,Lipemia Clearing Factor,Lipoprotein Lipase, Postheparin,Post Heparin Lipase
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010131 Aminosalicylic Acid An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid. 4-Aminosalicylic Acid,p-Aminosalicylic Acid,para-Aminosalicylic Acid,Alumino-4-Aminosalicylic Acid,Pamisyl,Rezipas,p-Aminosalicylic Acid Monolithium Salt,p-Aminosalicylic Acid Monopotassium Salt,p-Aminosalicylic Acid Monosodium Salt,p-Aminosalicylic Acid, Aluminum (2:1) Salt,p-Aminosalicylic Acid, Calcium (2:1) Salt,p-Aminosalicylic Acid, Monosodium Salt, Dihydrate,4 Aminosalicylic Acid,Acid, Aminosalicylic,Alumino 4 Aminosalicylic Acid,p Aminosalicylic Acid,p Aminosalicylic Acid Monolithium Salt,p Aminosalicylic Acid Monopotassium Salt,p Aminosalicylic Acid Monosodium Salt,para Aminosalicylic Acid
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005215 Fasting Abstaining from FOOD. Hunger Strike,Hunger Strikes,Strike, Hunger,Strikes, Hunger
D005260 Female Females

Related Publications

B Vessby, and H Lithell, and J Boberg, and K Hellsing
July 1950, Pharmaceutisch weekblad,
B Vessby, and H Lithell, and J Boberg, and K Hellsing
May 1948, Monthly bulletin of the Ministry of Health and the Public Health Laboratory Service,
B Vessby, and H Lithell, and J Boberg, and K Hellsing
October 1950, Casopis ceskeho lekarnictva,
B Vessby, and H Lithell, and J Boberg, and K Hellsing
November 1949, The Practitioner,
B Vessby, and H Lithell, and J Boberg, and K Hellsing
March 2008, Tuberculosis (Edinburgh, Scotland),
B Vessby, and H Lithell, and J Boberg, and K Hellsing
November 1951, Medical bulletin (Ann Arbor, Mich.),
B Vessby, and H Lithell, and J Boberg, and K Hellsing
September 1968, Tubercle,
B Vessby, and H Lithell, and J Boberg, and K Hellsing
March 1950, The Indian medical gazette,
B Vessby, and H Lithell, and J Boberg, and K Hellsing
September 1950, Journal de medecine de Lyon,
B Vessby, and H Lithell, and J Boberg, and K Hellsing
September 1948, Postgraduate medical journal,
Copied contents to your clipboard!